Rhythm Pharmaceuticals (RYTM) Revises LG Chem Deal And Adds $750 Million Loan, Is It Still Cheap?
Why Rhythm Pharmaceuticals Is Back In Focus
Rhythm Pharmaceuticals (RYTM) has returned to investor watchlists after amending its global license deal with LG Chem for bivamelagon and arranging a new US$750 million term loan facility.
Recent trading reflects that renewed attention. The 7 day share price return of 4.44% contrasts with a 90 day share price decline of 11.67%. At the same time, Rhythm Pharmaceuticals still carries a very large 5 year total shareholder return, suggesting long term holders have already experienced substantial gains even as shorter term momentum has cooled.
Scan how other rare disease and specialist healthcare stocks with funding in place are setting up for their next chapter with the hand picked list of solid balance sheet and fundamentals (24 results).
After a sharp multi year run and a fresh funding jolt, Rhythm Pharmaceuticals now sits in an awkward middle ground. Is most of the upside already cashed in, or does the recent move reset the valuation story?
Most Popular Narrative: 30% Undervalued
Rhythm Pharmaceuticals last closed at $93.44, while the most followed narrative on the stock, according to peter_4mgsy, points to a fair value of $134. That gap is feeding a view that the market is still not fully pricing in the rare disease obesity franchise or its pipeline.
Rhythm Pharmaceuticals is a high-growth commercial-stage company targeting orphan neuroendocrine disorders linked to MC4R pathway dysfunction (genetic obesity). Having expanded from one disorder to multiple approved indications, the company has additional opportunities ahead to expand its portfolio. I rate RYTM a BUY, driven by expected double-digit revenue growth, a broader targeted-obesity portfolio, and stronger-than-expected patient uptake.
See why 5 investors see Rhythm Pharmaceuticals as 30% undervalued.
Result: Fair Value of $134 (UNDERVALUED)
Still, Rhythm Pharmaceuticals carries clear pressure points, including ongoing net losses of US$210.222 million and clinical execution risk around its IMCIVREE and bivamelagon programs.
Find out about the key risks to this Rhythm Pharmaceuticals narrative.
Another View On Rhythm Pharmaceuticals Valuation
That $134 fair value from the narrative tells one story. The SWS DCF model tells another. On that framework, Rhythm Pharmaceuticals at $93.44 is priced well below an estimated future cash flow value of $474.53, which implies a very wide margin. Is that a genuine opportunity or just aggressive forecasting?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
If this all feels strongly optimistic on Rhythm Pharmaceuticals, that is the point. However, you still need to pressure test the numbers yourself. Start by reviewing the 3 key rewards.
Ready For More Investment Ideas Beyond Rhythm Pharmaceuticals?
Do not stop with a single opportunity. Broaden your watchlist with fresh setups that match your risk, income, and quality preferences using focused screeners on Simply Wall St.
- Target potential mispricings by scanning companies that combine quality fundamentals with attractive valuations through the 34 high quality undervalued stocks.
- Strengthen your income stream by focusing on reliable high-yield payers using the 4 dividend fortresses.
- Dial down portfolio stress and concentrate on resilient businesses with the 29 resilient stocks with low risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com